KLDiscovery Stock (OTC:KLDI), Trade Ideas

KLDiscovery Inc is a provider of technology-enabled services and software to help law firms, corporations, government agencies, and consumers solve complex data challenges. The company is engaged in providing technology-based litigation support solutions and services.

News

Financing

Small Cap

Tech

Media

KLDI

KLDiscovery Refinances Debt To Bolster Cash Flow

KLDiscovery Inc

Chipotle Mexican Grill, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CMG#NYSE">CMG</a>) reported financial results for the first quarter Wednesday after the bell. Here&#8217;s a rundown of the report and a look at why <a href="https://www.benzinga.com/pressreleases/24/04/n38415509/chipotle-announces-first-quarter-2024-results">shares are sizzling after hours</a>.
Q1 Earnings: Chipotle said first-quarter revenue increased 14.1% year-over-year to $2.702 billion, which beat the&nbsp;<a href="https://www.benzinga.com/calendars/earnings" target="_blank" rel="noreferrer noopener">consensus estimate</a>&nbsp;of $2.675 billion, according to&nbsp;<a href="https://benzinga.grsm.io/gxjhpowx7zks" target="_blank" rel="noreferrer noopener">Benzinga Pro</a>.&nbsp;The fast-casual restaurant chain company reported adjusted earnings of $13.37 per share, which beat analyst estimates of $11.68 per share.&nbsp;
Comparable restaurant sales increased 7% year-over-year due to higher transactions and a&nbsp;1.6%&nbsp;increase in average check. Digital sales represented 36.5% of food and beverage revenue. Operating margin was 16.3% in the first quarter, up from 15.5% year-over-year.&nbsp;
Chipotle said it opened 47 new restaurants in the quarter, and 43 of those locations included a Chipotlane. The company also repurchased $25 million of its stock during the first quarter and has $399.1 million remaining under its share repurchase authorization. 
&#8220;We had another outstanding quarter driven by our improvement in throughput and successful marketing initiatives, including Braised Beef&nbsp;Barbacoa and Chicken Al Pastor, which drove strong sales and transactions,&#8221; said&nbsp;Brian Niccol, chairman and CEO of Chipotle.
&#8220;The results we are seeing from our focus on developing exceptional people, preparing delicious food and fast throughput gives me confidence that we can achieve our long-term target of more than doubling our business in&nbsp;North America&nbsp;and expanding internationally.&#8221; 
Outlook: Chipotle expects full-year 2024 comparable restaurant sales growth in the mid- to high-single-digit range. The company anticipates opening between 285 and 315 new restaurants in 2024 with over 80% including a Chipotlane.
Chipotle shares appear to be responding favorably to the company&#8217;s better-than-expected results paired with an upbeat forecast for continued comparable sales growth. Chipotle&#8217;s first-quarter earnings call is scheduled for 4:30 p.m. ET.
Don&#8217;t Miss: <a href="https://www.benzinga.com/markets/cryptocurrency/24/04/38412499/treasury-yields-rise-tesla-jumps-on-cheaper-model-pledge-yen-plummets-to-34-year-lows-what">Treasury Yields Rise, Tesla Jumps On Cheaper Model Pledge, Yen Plummets To 34-Year Lows: What&#8217;s Driving Markets Wednesday?</a>
CMG Price Action:&nbsp;<a href="https://www.benzinga.com/quote/CMG" target="_blank" rel="noreferrer noopener">Chipotle shares</a>&nbsp;were up 3.30% after hours at $3,023.29 at the time of publication Wednesday, according to&nbsp;<a href="https://benzinga.grsm.io/gxjhpowx7zks" target="_blank" rel="noreferrer noopener">Benzinga Pro</a>.
Photo: Courtesy of Chipotle.

Earnings

Restaurants

After-Hours Center

Movers

Chipotle Mexican Grill Q1 Earnings: Revenue Beat, EPS Beat, Comparable Sales Up 7% And More

WLDS

Wearable Devices Granted 180-Day Extension By Nasdaq To Regain Compliance With Minimum Bid Requirement

Invited to Present Updated Endometrial Cancer Data During Special Session "ASCO Plenary Series: Rapid Abstract Updates"
NEWTON, Mass., April 24, 2024 /PRNewswire/ -- Karyopharm Therapeutics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KPTI#NASDAQ">KPTI</a>), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that several abstracts detailing new selinexor data have been selected for presentation at the 2024 American Society of Clinical Oncology Annual Meeting (2024&nbsp;ASCO Annual Meeting) being held May 31 - June 4 in Chicago, IL. The Company is pleased to have received an invitation to present updated Endometrial Cancer data during a special session called "ASCO Plenary Series: Rapid Abstract Updates."
A highlight at the 2024 ASCO Annual Meeting includes a rapid oral abstract update of long-term follow-up of selinexor maintenance in patients with TP53wt advanced or recurrent endometrial cancer – a pre-specified subgroup analysis from the Phase 3 ENGOT-EN5/GOG-3055/SIENDO Study.
"As we follow the endometrial cancer patients whose tumors are TP53wt and evaluate the long-term benefit, our confidence for selinexor to provide meaningful benefit for patients continues to grow," said Reshma Rangwala, MD, PhD, Chief Medical Officer of Karyopharm. "We are excited about the advancement of our three, phase three programs in areas of high unmet need in endometrial cancer, myelofibrosis, and multiple myeloma."
Details for the 2024 ASCO Annual Meeting abstracts are as follows:
<figure class="table"> 
<table>
<tbody>
<tr>
<td colspan="1" rowspan="1">Abstract Title</td>
<td colspan="1" rowspan="1">Presentation Type</td>
<td colspan="1" rowspan="1">Abstract #</td>
<td colspan="1" rowspan="1">Session Date/Time</td>
</tr>
<tr>
<td colspan="4" rowspan="1">Endometrial Cancer</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Updates on Abstract 427956: Long-Term Follow up of Selinexor Maintenance in Patients with TP53wt Advanced or Recurrent Endometrial Cancer—A Pre- Specified Subgroup Analysis from the Phase 3 ENGOT-EN5/GOG-3055/SIENDO Study (Rapid abstract update presentation following July 25, 2023 Plenary Series)</td>
<td colspan="1" rowspan="1">Rapid Oral</td>
<td colspan="1" rowspan="1">427956</td>
<td colspan="1" rowspan="1">
June 1, 2024 &nbsp;
12:30pm-1:30pm CDT
</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Phase 3 Dose Selection for Selinexor in TP53wt Endometrial Cancer Based on Exposure-Response Analysis</td>
<td colspan="1" rowspan="1">Poster</td>
<td colspan="1" rowspan="1">5594</td>
<td colspan="1" rowspan="1">
June 3, 2024 &nbsp;
9:00am – 12:00pm CDT
</td>
</tr>
<tr>
<td colspan="4" rowspan="1">Myelofibrosis</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Phase 3 Trial Design: Randomized Double-Blind Study Evaluating Selinexor, an XPO1 inhibitor, Plus Ruxolitinib in Jaki- Naïve Myelofibrosis</td>
<td colspan="1" rowspan="1">Poster</td>
<td colspan="1" rowspan="1">TPS6594</td>
<td colspan="1" rowspan="1">
June 3, 2024 &nbsp;
9:00am – 12:00pm CDT
</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Phase 2 Study Trial Design: Evaluating Selinexor Monotherapy in Patients with Jaki-Naïve Myelofibrosis and Moderate Thrombocytopenia</td>
<td colspan="1" rowspan="1">Poster</td>
<td colspan="1" rowspan="1">TPS6593</td>
<td colspan="1" rowspan="1">
June 3, 2024 &nbsp;
9:00am – 12:00pm CDT
</td>
</tr>
</tbody>
</table>
</figure>
About XPOVIO&#xAE; (selinexor) XPOVIO is a first-in-class, oral exportin 1 (XPO1) inhibitor and the first of Karyopharm's Selective Inhibitor of Nuclear Export (SINE) compounds to be approved for the treatment of cancer. XPOVIO functions by selectively binding to and inhibiting the nuclear export protein XPO1. XPOVIO is approved in the U.S. and marketed by Karyopharm in multiple oncology indications, including: (i) in combination with Velcade&#xAE; (bortezomib) and dexamethasone (XVd) in patients with multiple myeloma after at least one prior therapy; (ii) in combination with dexamethasone in patients with heavily pre-treated multiple myeloma; and (iii) in patients with diffuse large B-cell lymphoma (DLBCL), including DLBCL arising from follicular lymphoma, after at least two lines of systemic therapy. XPOVIO (also known as NEXPOVIO&#xAE; in certain countries) has received regulatory approvals in a growing number of ex-U.S. territories and countries, including&nbsp;Europe, the&nbsp;United Kingdom,&nbsp;South Korea,&nbsp;Israel,&nbsp;Singapore,&nbsp;Hong Kong, Mainland China,&nbsp;Australia,&nbsp;Canada,&nbsp;Taiwan&nbsp;and&nbsp;Macau&nbsp;and is marketed in those areas by Karyopharm's global partners. Selinexor is also being investigated in several other mid- and late-stage clinical trials across multiple high unmet need cancer indications, including in endometrial cancer and myelofibrosis.

Biotech

General

KPTI

Karyopharm Announces Presentations In Endometrial Cancer And Myelofibrosis At The 2024 American Society Of Clinical Oncology Annual Meeting

Guidance

CNMD

CONMED Sees FY24 Adj. EPS $4.25-$4.35 Vs $4.33 Est.; Revenue $1.330B-$1.355B Vs $1.350B Est.

Ford Motor Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/F#NYSE">F</a>) reported first-quarter financial results <a href="https://www.benzinga.com/calendars/earnings">after the market close Wednesday.</a>
Here are the key highlights.
What Happened: Ford reported first-quarter revenue of $42.8 billion, which was up 1.3% year-over-year. The revenue total beat a Street consensus estimate of $40.1 billion, according to<a href="https://www.benzinga.com/pro/feature/newsfeed?gspk=bHVrZWphY29iaTUzNDg&amp;gsxid=tdEE0VrK8Jeg&amp;ref=lukejacobi5348"> data from Benzinga Pro</a>.
The company reported earnings per share of 49 cents in the first quarter, which beat a Street estimate of 42 cents per share.
Revenue by segment for the first quarter was:
Ford Blue: $21.8 billion, -13% year-over-year
Ford Model e: $0.1 billion, -84% year-over-year
Ford Pro: $18.0 billion, +36% year-over-year
Wholesale units by segment were as follows:
Ford Blue: 626,000, -11% year-over-year
Ford Model e: 10,000, -20% year-over-year
Ford Pro: 409,000, +21% year-over-year
The company's Ford Pro unit saw strong growth led by high demand for Super Duty work trucks, Transit vans and software, the company said. The EBIT of the segment was up more than double.
The Model e division, which houseselectric vehicles, was affected by industrywide pricing pressure on EVs and posted an EBIT loss of $1.3 billion in the first quarter. Ford said it expects the Model e unit&#8217;s costs to improve going forward, but for the segment to face top-line pressure on sales.
"Customers want vehicles that they're passionate about, choices in how they're powered, quality that's constantly getting better and great value," Ford CEO Jim Farley said. 
"With Ford+, we're increasingly giving them all those things in ways that others don't and creating a company that will lead for the long haul."
Related Link: <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/04/38380272/ford-enjoys-bullish-momentum-but-faces-buying-pressure-ahead-of-q1-earnings">Ford Enjoys Bullish Momentum, Faces Buying Pressure Ahead Of Q1 Earnings</a>
What's Next: Ford is guiding for full-year adjusted earnings before interest and taxes to come in a range of $10 billion to $12 billion, unchanged from its previously announced guidance. The company said EBIT are tracking toward the higher end.
Ford&#8217;s guidance calls for adjusted free cash flow of between $6.5 billion and $7.5 billion for the full fiscal year, up from a previously announced range of $6 billion to $7 billion.
The company sees capital expenditures coming in a range of $8 billion to $9 billion for the full year, slightly improved from a prior range of $8 billion to $9.5 billion.
F Price Action: Ford shares are up 2.93% to $13.33 in after-hours trading Wednesday versus a 52-week trading range of $9.63 to $15.42.
Read Next: <a href="https://www.benzinga.com/news/24/04/38285214/fords-mustang-gallops-into-60th-year-still-a-pony-with-plenty-of-kick">Ford&#8217;s Mustang Gallops Into 60th Year: Still A Pony With Plenty Of Kick</a>
Photo courtesy of Ford.

Equities

Trading Ideas

Ford Q1 Earnings Highlights: Automaker Beats Street Estimates, Guidance Improves, EV Revenue Falls 84%

Kronos Bio, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KRON#NASDAQ">KRON</a>), a company dedicated to transforming the lives of those affected by cancer, today announced that it will present a study update of the oral CDK9 inhibitor KB-0742 in relapsed or refractory transcriptionally addicted advanced solid tumors from the ongoing Phase 1/2 trial, KB-0742-1001 (<a href="https://www.globenewswire.com/Tracker?data=QjH0e_MRq1WquJkxdHYjSAZIfnvGOasHqZswK9OfOcGY0UH83vAQfyaV3FypSmcxIINZCYMZXpa4XArWukfeghvgg8oFwMYtc06ED7zOgMw59gW6ANyeKC_67qe-OywG5Uasdhoi49nvxZgPR1Tlsw==">NCT04718675</a>), at the American Society of Clinical Oncology (ASCO) Annual Meeting, being held from May 31 – June 4, 2024 in Chicago, Illinois and online. &nbsp;
"We are looking forward to sharing updated data from KB-0742-1001, our ongoing Phase 1/2 trial of KB-0742, including data from the 80mg three days on/four days off dosing regimen. The trial is designed to assess the safety, tolerability, and preliminary efficacy at increasing dose levels of KB-0742, an orally bioavailable and selective CDK9 inhibitor with a long half-life," said Norbert Bischofberger, Ph.D., chief executive officer and president of Kronos Bio. "Our last update at the 2023 AACR-NCI-EORTC meeting showed that KB-0742 exhibited anti-tumor activity while maintaining an acceptable safety profile at the 60mg three-days-on, four-days-off dose, which is an important step as we seek to identify the optimal dose of KB-0742."
Details for the ASCO 2024 abstract are as follows:
Title: Study update of the oral CDK9 inhibitor KB-0742 in relapsed or refractory transcriptionally addicted advanced solid tumors Presenter: Brian A. Van Tine, M.D., Ph.D., Washington University in St. Louis Abstract ID#: 3102 Poster Session: Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology Location: Hall A, McCormick Place, Chicago, Illinois Poster Board #: 247 Date and Time: Saturday, June 1, 2024, from 9:00 a.m. to 12:00 p.m. CDT

KRON

Kronos Bio To Present Clinical Update On Phase 1/2 Trial Of KB-0742 At The 2024 ASCO Annual Meeting

PLXS

Plexus Continues To Anticipate Strong Finish To FY24 With Expansion In Revenue And Non-GAAP Operating Margin Each Quarter

Meritage Homes (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MTH#NYSE">MTH</a>) reported quarterly earnings of $5.06 per share which beat the analyst consensus estimate of $3.55 by 42.54 percent. The company reported quarterly sales of $1.468 billion which beat the analyst consensus estimate of $1.288 billion by 14.01 percent. This is a 14.78 percent increase over sales of $1.279 billion the same period last year.

Earnings Beats

Meritage Homes Q1 2024 GAAP EPS $5.06 Beats $3.55 Estimate, Sales $1.468B Beat $1.288B Estimate

Alerus Finl (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALRS#NASDAQ">ALRS</a>) reported quarterly earnings of $0.32 per share which met the analyst consensus estimate. This is a 20 percent decrease over earnings of $0.40 per share from the same period last year. The company reported quarterly sales of $47.542 million which beat the analyst consensus estimate of $47.448 million by 0.20 percent. This is a 2.80 percent decrease over sales of $48.911 million the same period last year.

ALRS

Alerus Finl Q1 2024 GAAP EPS $0.32, Inline, Sales $47.542M Beat $47.448M Estimate

Plexus Sees Q3 Revenue Of $960M-$1.00B (Est $1.022B), Adj EPS Of $1.22-$1.37 (Est $1.09)

SLM Sees FY24 EPS $2.60-$2.70 Vs $2.69 Est

SLM (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLM#NASDAQ">SLM</a>) reported quarterly earnings of $1.27 per share which beat the analyst consensus estimate of $1.07 by 18.69 percent. This is a 170.21 percent increase over earnings of $0.47 per share from the same period last year. The company reported quarterly sales of $387.00 million which missed the analyst consensus estimate of $387.89 million by 0.23 percent. This is a 4.46 percent decrease over sales of $405.07 million the same period last year.

Earnings Misses

SLM Q1 Adj $1.27 Beats $1.07 Estimate, Sales $387.00M Miss $387.89M Estimate

Wyndham Hotels & Resorts Raises FY24 Adjusted EPS Outlook From $4.11-$4.23 To $4.18-$4.30, Est $4.21

Horizon Bancorp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HBNC#NASDAQ">HBNC</a>) reported quarterly earnings of $0.32 per share which beat the analyst consensus estimate of $0.31 by 3.23 percent. This is a 25.58 percent decrease over earnings of $0.43 per share from the same period last year. The company reported quarterly sales of $53.217 million which missed the analyst consensus estimate of $54.377 million by 2.13 percent. This is a 2.99 percent decrease over sales of $54.857 million the same period last year.

HBNC

Horizon Bancorp Q1 2024 Adj EPS $0.32 Beats $0.31 Estimate, Sales $53.217M Miss $54.377M Estimate

WIIM

VIST

Vista Energy shares are trading lower after the company reported worse-than-expected Q1 financial results.

2024 Guidance
The Company has increased the low end of its previously issued fully diluted 2024 AFFO per share estimate and now expects that 2024 AFFO per share on a fully diluted basis will be within a range of $1.72 to $1.75.
Note: The Company does not provide guidance for the most comparable GAAP financial measure, net income, or a reconciliation of the forward-looking non-GAAP financial measure of AFFO to net income computed in accordance with GAAP, because it is unable to reasonably predict, without unreasonable efforts, certain items that would be contained in the GAAP measure, including items that are not indicative of the Company's ongoing operations, such as, without limitation, potential impairments of real estate assets, net gain/loss on dispositions of real estate assets, changes in allowance for credit losses and stock-based compensation expense. These items are uncertain, depend on various factors, and could have a material impact on the Company's GAAP results for the guidance period.

EPRT

Essential Properties Realty Trust Updates 2024 AFFO Guidance To $1.72-$1.75 per Share

BMRN

BioMarin Pharmaceutical shares are trading lower after the company reported Q1 financial results.

O'Reilly Automotive (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ORLY#NASDAQ">ORLY</a>) reported quarterly earnings of $9.27 per share which beat the analyst consensus estimate of $9.26 by 0.11 percent. The company reported quarterly sales of $3.98 billion which met the analyst consensus estimate. This is a 7.34 percent increase over sales of $3.71 billion the same period last year.

ORLY

O'Reilly Automotive Q1 2024 Adj EPS $9.27 Beats $9.26 Estimate, Sales $3.98B Inline

QuantumScape (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/QS#NYSE">QS</a>) reported quarterly losses of $(0.24) per share which met the analyst consensus estimate. This is unchanged from the same period last year.

QuantumScape Q1 2024 GAAP EPS $(0.24), Inline

GSHD

Goosehead Insurance Sees FY24 Revenue $290M-$310M Vs $312.208M Est.

KLDiscovery reports Q1 results

KLDiscovery GAAP EPS of -$0.11, revenue of $90M

KLDiscovery GAAP EPS of -$0.26, revenue of $79.3M

KLDiscovery GAAP EPS of -$0.33, revenue of $85.8M

Press Releases

KLDiscovery introduces cutting-edge Alerting feature in its Client Portal, once again raising the standards of client support in the eDiscovery legal services industry

KLDiscovery Inc. Announces Third Quarter 2023 Financial Results

KLDiscovery Inc. Completes Acquisition of Cenza Technologies Private Limited

Nebula® achieves significant growth across the global eDiscovery landscape

KLDiscovery Achieves Significant Milestone with Full Integration of All Back-Office and Operational Systems

KLDiscovery's eDiscovery Franchise Program Is Now Available in All 50 US States

KLDiscovery Inc. to Report Fourth Quarter and Full-Year 2023 Financial Results on March 27, 2024; Conference Call 8:30 AM ET March 28, 2024

KLDiscovery Inc. Announces Fourth Quarter and Full-Year 2023 Financial Results

KLDiscovery Investments Lead to a Record-Breaking Year in 2023

KLDiscovery Announces Major Expansion of Capabilities in ReadySuite® 8

KLDiscovery